Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126746921 | 12674692 | 1 | I | 20160808 | 20160823 | 20160823 | EXP | CN-CIPLA LTD.-2016CN17284 | CIPLA | 0.00 | Y | 0.00000 | 20160823 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126746921 | 12674692 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | AREA UNDER THE CONCENTRATION TIME CURVE 6.0 (770 MG/DL) | U | U | 77383 | ||||||||
| 126746921 | 12674692 | 2 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | 1250 MG/M2, UNK | U | U | 0 | 1250 | MG/M**2 | ||||||
| 126746921 | 12674692 | 3 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 126746921 | 12674692 | 4 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 126746921 | 12674692 | 5 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | 175 MG/M2, (300 MG/DL) | U | U | 0 | 175 | MG/M**2 | ||||||
| 126746921 | 12674692 | 6 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 75 MG/M2, UNK | U | U | 0 | 75 | MG/M**2 | ||||||
| 126746921 | 12674692 | 7 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 126746921 | 12674692 | 8 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 126746921 | 12674692 | 9 | SS | BEVACIZUMAB MONOCLONAL ANTIBODY (MAB) | BEVACIZUMAB | 1 | Unknown | 15 MG/KG, (900MG/DL) | 54 | G | U | U | 0 | 15 | MG/KG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126746921 | 12674692 | 1 | Lung cancer metastatic |
| 126746921 | 12674692 | 2 | Lung cancer metastatic |
| 126746921 | 12674692 | 3 | Disease progression |
| 126746921 | 12674692 | 5 | Lung cancer metastatic |
| 126746921 | 12674692 | 6 | Lung cancer metastatic |
| 126746921 | 12674692 | 7 | Disease progression |
| 126746921 | 12674692 | 9 | Lung cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126746921 | 12674692 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126746921 | 12674692 | Alopecia | |
| 126746921 | 12674692 | Bone marrow failure | |
| 126746921 | 12674692 | Disease progression | |
| 126746921 | 12674692 | Epistaxis | |
| 126746921 | 12674692 | Neutropenia | |
| 126746921 | 12674692 | Proteinuria | |
| 126746921 | 12674692 | Thrombocytopenia | |
| 126746921 | 12674692 | Toxic neuropathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126746921 | 12674692 | 2 | 20120531 | 0 | ||
| 126746921 | 12674692 | 3 | 20120815 | 0 | ||
| 126746921 | 12674692 | 4 | 20120906 | 0 | ||
| 126746921 | 12674692 | 6 | 20120531 | 0 | ||
| 126746921 | 12674692 | 7 | 20120815 | 0 | ||
| 126746921 | 12674692 | 8 | 20120906 | 0 | ||
| 126746921 | 12674692 | 9 | 20080423 | 20120116 | 0 |